Mind the gap - Managing tuberculosis across the disease spectrum

EBioMedicine. 2022 Apr:78:103928. doi: 10.1016/j.ebiom.2022.103928. Epub 2022 Mar 23.

Abstract

We currently have a binomial approach to managing tuberculosis. Those with active disease, ideally confirmed microbiologically, are treated with a standard 6-month, multi-drug regimen and those with latent infection and no evidence of disease with shorter, one or two drug regimens. Clinicians frequently encounter patients that fall between these two management pathways with some but not all features of disease and this will occur more often with the increasing emphasis on chest X-ray-based systematic screening. The view of tuberculosis as a spectrum of disease states is being increasingly recognised and is leading to new diagnostic approaches for early disease. However, the 6-month regimen for treating disease was driven by the duration required to treat the most extensive forms of pulmonary TB and shorter durations appear sufficient for less extensive disease. It is time undertake clinical trials to better define the optimal treatment for tuberculosis across the disease spectrum.

Keywords: Diagnosis; Disease spectrum; Subclinical disease; Treatment; Tuberculosis.

Publication types

  • Review

MeSH terms

  • Antitubercular Agents / therapeutic use
  • Humans
  • Tuberculosis* / diagnosis
  • Tuberculosis* / drug therapy
  • Tuberculosis* / epidemiology
  • Tuberculosis, Pulmonary* / diagnosis
  • Tuberculosis, Pulmonary* / drug therapy

Substances

  • Antitubercular Agents